Table 1.
Baseline Characteristics at Ramp Test
| N=88 | |
|---|---|
| Demographics | |
| Age, y | 61 (53, 67) |
| Sex, male | 53 (60%) |
| Race, white | 49 (56%) |
| Body mass index | 27.6 (24.0, 34.6) |
| Preramp LVAD duration, d | 236 (91, 647) |
| Nonischemic cause | 51 (58%) |
| Destination therapy | 67 (76%) |
| Post-LVAD exchange | 2 (2%) |
| Device | |
| HeartMate II | 57 (65%) |
| HVAD | 31 (35%) |
| Comorbidity | |
| Hypertension | 49 (56%) |
| Diabetes mellitus | 36 (41%) |
| History of stroke | 13 (15%) |
| Atrial fibrillation | 34 (39%) |
| History of ventricular tachyarrhythmias | 18 (21%) |
| New York Heart Association functional class | |
| Class I | 35 (40%) |
| Class II | 48 (55%) |
| Class III | 5 (5%) |
| Laboratory data | |
| Hemoglobin, g/dL | 11.8±1.7 |
| Hematocrit, % | 36.4 (33.7, 38.5) |
| eGFR, mL/(min·1.73 m2) | 54 (39, 71) |
| Serum total bilirubin, mg/dL | 0.6 (0.4, 0.8) |
| Preramp readmission rate | |
| Total readmission rate, events/y | 1.13 |
| HF readmission rate, events/y | 0.16 |
| Non-HF readmission rate, events/y | 0.97 |
Data are expressed as n (%), mean±SD, or median (25% quartile, 75% quartile). eGFR indicates estimated glomerular filtration rate; HF, heart failure; and LVAD, left ventricular assist device.